Prestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Established in 2005, Prestige Inhome Care is the leading in-home aged and NDIS care provider in Australia with over 1,800 clients, serviced by a team of more than 1,000 registered nurses and professional carers. Prestige provides first-class, premium care to its clientele across Victoria, NSW and Queensland, allowing them to stay in the comfort of their own home.
Oaklins’ team in Australia acted as corporate advisor to the shareholders of Prestige, who were seeking an investment partner to provide growth capital. The team worked closely alongside Prestige through a comprehensive investor roadshow process to find the right-fit investor to support Prestige’s future growth. The transaction adds to Oaklins’ track record advising founder-owned businesses on sourcing institutional growth capital and support that will help catapult the business to another level of success.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Ver másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Ver másAmcomri Group has completed an initial public offering
Amcomri Group plc has successfully completed an initial public offering (IPO) on the AIM Market of the London Stock Exchange, successfully raising US$15 million (£12 million) through a placing. The IPO will enable Amcomri to further its ‘Buy-Improve-Build’ strategy in the UK engineering sector.
Ver más